Cytodel

About Cytodel

Cytodel Inc. is a preclinical-stage biopharmaceutical company that emerged in 2012 to commercialize research developed by its founders at the NYU-Grossman School of Medicine. The company holds an exclusive license from NYU for a patented technology platform centered on producing recombinant derivatives of botulinum neurotoxin (BoNT), the active ingredient in products like Botox®. One of the company's founders, Dr. Philip Band, serves as CEO and is a co-inventor of the core technology. His background includes experience at biotechnology startups and academic roles at NYU, where his work on botulinum toxin began.

The core of Cytodel's business is a technology platform that engineers recombinant BoNT (rBoT) derivatives. Unlike existing BoNT products, which are derived from native bacteria and cannot be easily modified, Cytodel uses molecular biology to create novel molecules with customized properties. This proprietary process allows the company to develop atoxic or less toxic versions of BoNT that retain the toxin's ability to specifically target and enter neurons. This creates a molecular vehicle capable of delivering therapeutic payloads, such as antibodies, directly into the neuronal cytoplasm—a cellular space previously inaccessible to conventional antibody treatments. This intraneuronal delivery system is the key differentiator, enabling the company to pursue treatments for a range of nervous system disorders.

Cytodel's business model focuses on developing a pipeline of novel therapeutics for high-value medical needs. The company's lead program, Cyto-111, is a BoNT-based Antibody Fusion Protein designed as an antidote to botulism by delivering a neutralizing nanobody inside affected neurons. Preclinical studies have shown its effectiveness in animal models where traditional antibodies fail. Another program, Cyto-014, is a "Biobetter" BoNT being developed for therapeutic use in large muscles, engineered to offer an improved safety margin compared to existing treatments. Beyond these, Cytodel is leveraging its platform for discovery programs targeting chronic pain and neurodegenerative diseases by using neuronal circuits as a delivery pathway to the central nervous system. The company has secured approximately $4.05 million across five funding rounds, including seed funding and grants, with notable investors including Kairos Ventures and the Department of Health and Human Services (HHS).